January 12, 2021 -- Tessera Therapeutics has raised over $230 million in series B financing to advance its gene writing technology, capable of writing therapeutic instructions into the genome to treat diseases at their source.
Gene writing works by changing any base pair to another, making small insertions or deletions, and writing entire genes into the genome to unlock the potential to cure genetic diseases and create life-changing therapeutics in cardiovascular, oncological, neurodegenerative, and infectious diseases.
The technology is based on mobile genetic elements. Tessera's computational and high-throughput platform has enabled the team to design, build, and test thousands of engineered and synthetic mobile genetic elements for writing and rewriting the human genome. The platform overcomes limitations of current gene editing and gene therapies by engineering the genome without making double stranded breaks, being able to make any base pair change, permanently adding new DNA, and being delivered by RNA only.
The company will use the funds to accelerate research and development of the technology platform, expand its team, and establish manufacturing and automation capabilities. Tessera was founding by Flagship Pioneering.
The round of financing was led by the Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2i.